6533b826fe1ef96bd1283d8e

RESEARCH PRODUCT

Assessment of tumor microcirculation with dynamic contrast-enhanced MRI in patients with esophageal cancer: initial experience.

Wolfgang SchreiberAndreas PohlmannKatja OberholzerPeter MildenbergerHeinz SchmidbergerTheodor JungingerCristoph DüberPeter Kunz

subject

AdultGadolinium DTPAMalemedicine.medical_specialtyEsophageal NeoplasmsUrologyContrast MediaAdenocarcinomaMicrocirculationlaw.inventionRandomized controlled triallawmedicineCarcinomaImage Processing Computer-AssistedHumansRadiology Nuclear Medicine and imagingAgedObserver Variationmedicine.diagnostic_testbusiness.industryMicrocirculationTherapeutic effectMagnetic resonance imagingEsophageal cancerMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance ImagingTreatment OutcomeDynamic contrast-enhanced MRICarcinoma Squamous CellFeasibility StudiesHistopathologyFemaleRadiologybusiness

description

PURPOSE: To investigate the feasibility and impact of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) on tumor characterization and response to radiochemotherapy (RCT) in patients with esophageal cancer. MATERIALS AND METHODS: A total of 48 patients underwent DCE-MRI to assess tumor microcirculation based on a two-compartment model function. Effects of RCT on kinetic parameters were studied in 12 patients with squamous cell carcinoma. RESULTS: Tumor microcirculation differs with respect to histological subtype: squamous cell carcinomas showed lower values of amplitude A (leakage space, P = 0.015) and higher contrast agent exchange rates (k(21), P = 0.225) compared with adenocarcinomas. RCT led to a significant decrease of the contrast agent exchange rate (P = 0.005), while amplitude A increased moderately after therapy (P = 0.136). CONCLUSION: DCE-MRI is feasible in patients with esophageal cancer, reveals therapeutic effects, and may thus be useful in therapy management and monitoring.

10.1002/jmri.21305https://pubmed.ncbi.nlm.nih.gov/18504749